Refine by
Medical Data Articles & Analysis
98 news found
BC Platforms has embedded NVIDIA accelerated computing into BC Mosaic, its trusted research environment, enabling faster GPU-powered analytics and AI-led analyses across clinical, multi-omics, and real-world data to support precision medicine and accelerated drug development.NVIDIA integration in BC MosaicNVIDIA technology is now natively available within BC Mosaic, providing ...
Cameron shares invaluable leadership and entrepreneurial insights, reflecting on the journey of founding and growing Synaptive globally, how he leverages artificial intelligence to enhance surgical outcomes and streamline medical procedures, and the importance of data collection in improving patient care and surgical precision. ...
The launch of Caresyntax CDaaS follows the recently announced addition of CQInsights (CQI) and appointment of Dr. Bruce Ramshaw as Chief Medical Informatics Officer (CMIO) for Caresyntax. The integration of the CQI solution into the Caresyntax platform enables a stack of technologies and capabilities with new digital workflows that can acquire curated data and ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
While medical AI has many potential benefits, there are challenges that have not been tackled yet. One of the major challenges is the limited generalizability of many AI algorithms. Applying a medical AI algorithm that is trained in hospital A may give unexpected results when applied in hospital B. Why does this happen? Certain parameters are different between hospitals. If hospital A has Siemens ...
Anonymized medical data sharing is necessary for the advancement of medicine, but it requires a tremendous amount of trust from all stakeholders. ...
It will conduct multiple trial emulations in various data sources, beginning with a one-year focus on oncology. Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care. “xCures has implemented real-time access to retrospective and ...
ByxCures
” BioIntelliSense’s medical-grade BioButton® wearable device, along with its algorithmic-based data services, enable effortless remote data capture and continuous multi-parameter monitoring on a single device in both acute and postacute settings. ...
The webcast will cover the unmet medical need in MDD, review clinical data generated with zuranolone to date and provide more detail on the potential commercialization plans and opportunity in MDD, if zuranolone is approved. ...
You will no longer have to wait for days for a central diagnostic laboratory to provide critical medical test data regarding your health. This program showcases a range of young diagnostic companies that are poised to launch exciting products and services that will truly change your ...
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). ...
Medical robotics innovator Noah Medical provided physicians attending the American College of Chest Physicians 2022 meeting with a preview of study data documenting its high tool in lesion rate. ...
By integrating xCures’ rich real-world longitudinal clinical data with mProbe’s cancer proteomics panels, the two companies are working to expedite the discovery of predictive, diagnostic, and prognostic biomarkers for cancer. ...
ByxCures
From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making this important service convenient and accessible is key to improving health care quality and ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). The data was presented during ...
The most common adverse events associated with zuranolone included headache, somnolence, dizziness and sedation. Data from a post-hoc analysis of 4 studies in the LANDSCAPE program demonstrated that improvements in depressive symptoms with zuranolone at Day 15 were sustained beyond the end of treatment. ...
Proprio’s vice president of product management and marketing, Tommy Carls, has been featured in Medical Device and Diagnostic Industry (“MD&DI”). Carls’ thought leadership piece, “Bringing Intentionality & Defined Purpose to the Road to Data Intelligence” highlights the undervalued influence of healthcare ...
However, results recently published from a single-center feasibility study at Macquarie University Hospital in Australia showed that the AeriSeal System successfully closed collateral air channels and allowed for successful clinical outcomes after treatment with Zephyr Valves.2 At 6 months, AeriSeal and Zephyr Valve treated CV+ patients experienced clinically meaningful improvements similar to ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular ...
FBX-101 clinical data demonstrating safety and initial efficacy from the RESKUE trial is being presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180 FBX-101 significantly increased ...